Phreesia, Inc. (NYSE:PHR – Get Free Report) General Counsel Allison C. Hoffman sold 3,982 shares of Phreesia stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $26.61, for a total transaction of $105,961.02. Following the transaction, the general counsel now directly owns 159,137 shares in the company, valued at $4,234,635.57. This trade represents a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Phreesia Stock Performance
NYSE PHR opened at $28.42 on Friday. The stock has a market cap of $1.65 billion, a PE ratio of -19.33 and a beta of 0.94. The company has a current ratio of 1.74, a quick ratio of 1.77 and a debt-to-equity ratio of 0.04. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $29.16. The stock has a fifty day simple moving average of $22.70 and a 200-day simple moving average of $22.57.
Phreesia (NYSE:PHR – Get Free Report) last posted its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The company had revenue of $106.80 million for the quarter, compared to analyst estimates of $106.33 million. During the same quarter last year, the company earned ($0.58) EPS. Phreesia’s revenue for the quarter was up 16.6% compared to the same quarter last year. Equities analysts anticipate that Phreesia, Inc. will post -1.16 earnings per share for the current year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
A number of research analysts have issued reports on PHR shares. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and boosted their price objective for the company from $24.00 to $32.00 in a research report on Wednesday. Robert W. Baird decreased their target price on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. JMP Securities reaffirmed a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a research report on Tuesday, December 10th. KeyCorp upped their price target on shares of Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Truist Financial increased their target price on shares of Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Eleven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Phreesia has an average rating of “Buy” and an average target price of $30.64.
Check Out Our Latest Stock Analysis on PHR
About Phreesia
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Read More
- Five stocks we like better than Phreesia
- What Are Dividend Champions? How to Invest in the Champions
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- 3 Monster Growth Stocks to Buy Now
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Which Wall Street Analysts are the Most Accurate?
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.